[en] Knee osteoarthritis (OA) is one of the most common and disabling medical conditions. In the case of moderate to severe pain, a single intervention may not be sufficient to allay symptoms and improve quality of life. Examples include first-line, background therapy with symptomatic slow-acting drugs for OA (SYSADOAs) or non-steroidal anti-inflammatory drugs (NSAIDs). Therefore, the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) performed a review of a multimodal/multicomponent approach for knee OA therapy. This strategy is a particularly appropriate solution for the management of patients affected by knee OA, including those with pain and dysfunction reaching various thresholds at the different joints. The multimodal/multicomponent approach should be based, firstly, on different combinations of non-pharmacological and pharmacological interventions. Potential pharmacological combinations include SYSADOAs and NSAIDs, NSAIDs and weak opioids, and intra-articular treatments with SYSADOAs/NSAIDs. Based on the available evidence, most combined treatments provide benefit beyond single agents for the improvement of pain and other symptoms typical of knee OA, although further high-quality studies are required. In this work, we have therefore provided new, patient-centered perspectives for the management of knee OA, based on the concept that a multimodal, multicomponent, multidisciplinary approach, applied not only to non-pharmacological treatments but also to a combination of the currently available pharmacological options, will better meet the needs and expectations of patients with knee OA, who may present with various phenotypes and trajectories.
Disciplines :
Public health, health care sciences & services
Author, co-author :
Veronese, Nicola
Cooper, Cyrus ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Al-Daghri, Nasser ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Branco, Jaime
Cavalier, Etienne ; Centre Hospitalier Universitaire de Liège - CHU > > Service de chimie clinique
Cheleschi, Sara
da Silva Rosa, Mario Coelho
Conaghan, Philip G.
Dennison, Elaine M.
de Wit, Maarten
Fioravanti, Antonella
Fuggle, Nicholas R.
Haugen, Ida K.
Herrero-Beaumont, Gabriel
Honvo, Germain ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Laslop, Andrea
Matijevic, Radmila
Migliore, Alberto
Mobasheri, Ali ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Pelletier, Jean-Pierre
Prieto Yerro, María Concepción
Radermecker, Régis ; Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques
Rannou, François
Rizzoli, René ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet. 2012;380(9859):2197–223.
Cui A, Li H, Wang D, Zhong J, Chen Y, Lu H. Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies. EClinicalMedicine. 2020;29: 100587.
Bruyère O, Honvo G, Veronese N, Arden NK, Branco J, Curtis EM, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337–50.
Bannuru RR, Osani M, Vaysbrot E, Arden N, Bennell K, Bierma-Zeinstra S, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthr Cartil. 2019;27(11):1578–89.
Arden NK, Perry TA, Bannuru RR, Bruyère O, Cooper C, Haugen IK, et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nat Rev Rheumatol. 2021;17(1):59–66.
Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee American College of Rheumatology. Arthritis Rheum. 1995;38(11):1541–6.
Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol. 2020;72(2):220–33.
Parry EL, Thomas MJ, Peat G. Defining acute flares in knee osteoarthritis: a systematic review. BMJ Open. 2018;8(7): e019804.
Hiligsmann M, Pinto D, Dennison E, Al-Daghri N, Beaudart C, Branco J, et al. Patients’ preferences for osteoarthritis treatment: the value of stated-preference studies. Springer; 2019. p. 1–3.
de Wit M, Cooper C, Reginster J-Y. Practical guidance for patient-centred health research. The Lancet. 2019;393(10176):1095–6.
de Wit M, Cooper C, Tugwell P, Bere N, Kirwan J, Conaghan PG, et al. Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clin Exp Res. 2019;31(7):905–15.
Yeap SS, Tanavalee A, Perez EC, Tan MP, Reyes BHM, Lee JK, et al. 2019 revised algorithm for the management of knee osteoarthritis: the Southeast Asian viewpoint. Aging Clin Exp Res. 2021;33(5):1149–56.
Zhang Z, Huang C, Cao Y, Mu R, Zhang MC, Xing D, et al. 2021 revised algorithm for the management of knee osteoarthritis—the Chinese viewpoint. Aging Clin Exp Res. 2021;33(8):2141–7.
Denisov L, Tsvetkova E, Golubev G. Algoritm lecheniya osteoartrita kolennogo sustava Evropeiskogo obschestva po klinicheskim I ekonomicheskim aspektam osteoporoza I osteoartrita (ESCEO) primenim v rossiiskoi klinicheskoi praktike: sovmestnoe zaklyuchenie veduschikh rossiiskikh spetsialistov i ekspertov ESCEO po osteoartritu [The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis is applicable to Russian clinical practice: a consensus statement of leading russian and ESCEO osteoarthritis experts]. Nauchno-prakticheskaya revmatologiya (Rheumatology Science and Practice). 2016;54(6):641–53.
Kucharz EJ, Szántó S, Ivanova Goycheva M, Petronijević M, Šimnovec K, Domżalski M, et al. Endorsement by Central European experts of the revised ESCEO algorithm for the management of knee osteoarthritis. Rheumatol Int. 2019;39(7):1117–23.
Zeng C, Doherty M, Persson MS, Yang Z, Sarmanova A, Zhang Y, et al. Comparative efficacy and safety of acetaminophen, topical and oral non-steroidal anti-inflammatory drugs for knee osteoarthritis: evidence from a network meta-analysis of randomized controlled trials and real-world data. Osteoarthr Cartil. 2021;29(9):1242–51.
da Costa BR, Pereira TV, Saadat P, Rudnicki M, Iskander SM, Bodmer NS, et al. Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis. BMJ. 2021;375:n2321.
Conaghan PG, Arden N, Avouac B, Migliore A, Rizzoli R. Safety of paracetamol in osteoarthritis: what does the literature say? Drugs Aging. 2019;36(1):7–14.
Wolff DG, Christophersen C, Brown SM, Mulcahey MK. Topical nonsteroidal anti-inflammatory drugs in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Phys Sportsmed. 2021;49(4):381–91.
Pincus T, Koch G, Lei H, Mangal B, Sokka T, Moskowitz R, et al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis. 2004;63(8):931–9.
Patel J, Ladani A, Sambamoorthi N, LeMasters T, Dwibedi N, Sambamoorthi U. A machine learning approach to identify predictors of potentially inappropriate non-steroidal anti-inflammatory drugs (NSAIDs) use in older adults with osteoarthritis. Int J Environ Res Public Health. 2021;18(1):155.
Álvarez-Soria MA, Largo R, Santillana J, Sánchez-Pernaute O, Calvo E, Hernández M, et al. Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. Ann Rheum Dis. 2006;65(8):998–1005.
Huang H, Luo M, Liang H, Pan J, Yang W, Zeng L, et al. Meta-analysis comparing celecoxib with diclofenac sodium in patients with knee osteoarthritis. Pain Med. 2021;22(2):352–62.
Alvarez-Soria M, Herrero-Beaumont G, Moreno-Rubio J, Calvo E, Santillana J, Egido J, et al. Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis. Osteoarthritis Cartilage. 2008;16(12):1484–93.
Cheleschi S, Tenti S, Giannotti S, Veronese N, Reginster J-Y, Fioravanti A. A combination of celecoxib and glucosamine sulfate has anti-inflammatory and chondroprotective effects: results from an in vitro study on human osteoarthritic chondrocytes. Int J Mol Sci. 2021;22(16):8980.
Rovati LC, Girolami F, Persiani S. Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties. Ther Adv Musculoskelet Dis. 2012;4(3):167–80.
Noyszewski EA, Wroblewski K, Dodge GR, Kudchodkar S, Beers J, Sarma A, et al. Preferential incorporation of glucosamine into the galactosamine moieties of chondroitin sulfates in articular cartilage explants. Arthritis Rheum. 2001;44(5):1089–95.
Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, Van De Putte L. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum. 2000;43(1):4–13.
Zweers MC, de Boer TN, van Roon J, Bijlsma JW, Lafeber FP, Mastbergen SC. Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis. Arthritis Res Ther. 2011;13(5):1–11.
Amuzadeh F, Kazemian G, Rasi AM, Khazanchin A, Khazanchin A, Kazemi P. Comparison of the efficacy of combination of glucosamine sulfate and celecoxib versus celecoxib alone for the pain, morning stiffness, function relief of females with osteoarthritis grade 1&2 of the knee (a comparative study). Indian J Fundam Appl Life Sci. 2015;5:129–36.
Zhijun L, Rongchun C, Feixiang L, Yaohong W, Ning L, Shufang Z, et al. Therapeutic effects of combined meloxicam and glucosamine sulfate treatment on patients with osteoarthritis, and its effect on serum CTX-I, CTX-II, COMP and MMP-3. Trop J Pharm Res. 2019;18(7):1553–7.
Selvan T, Rajiah K, Nainar M, Mathew EM. A clinical study on glucosamine sulfate versus combination of glucosamine sulfate and NSAIDs in mild to moderate knee osteoarthritis. Scientific World J. 2012;2012: 902676.
Gang D, Xiaguang C, Kanghua Y, Aiping W, Guangxuan Z. Combined effect of celecoxib and glucosamine sulfate on inflammatory factors and oxidative stress indicators in patients with knee osteoarthritis. Trop J Pharm Res. 2019;18(2):397–402.
Sun Y, Wang C, Gong C. Repairing effects of glucosamine sulfate in combination with etoricoxib on articular cartilages of patients with knee osteoarthritis. J Orthop Surg Res. 2020;15(1):1–9.
Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. The Lancet. 2010;376(9736):173–9.
Chan FK, Ching JY, Tse YK, Lam K, Wong GL, Ng SC, et al. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. The Lancet. 2017;389(10087):2375–82.
Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002;347(26):2104–10.
Cryer B, Li C, Simon LS, Singh G, Stillman MJ, Berger MF. GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. Am J Gastroenterol. 2013;108(3):392.
Green GA. Understanding NSAIDs: from aspirin to COX-2. Clin Cornerstone. 2001;3(5):50–9.
Amaechi O, Huffman MM, Featherstone K. Pharmacologic therapy for acute pain. Am Fam Physician. 2021;104(1):63–72.
McNicol ED, Strassels S, Goudas L, Lau J, Carr DB. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database of Syst Rev. 2005;1:CD005180.
Marret E, Kurdi O, Zufferey P, Bonnet F, Warltier DC. Effects of nonsteroidal antiinflammatory drugs on patient-controlled analgesia morphine side effects: meta-analysis of randomized controlled trials. J Am Soc Anesthesiolog. 2005;102(6):1249–60.
Quiding H, Grimstad J, Rusten K, Stubhaug A, Bremnes J, Breivik H. Ibuprofen plus codeine, ibuprofen, and placebo in a single- and multidose cross-over comparison for coxarthrosis pain. Pain. 1992;50(3):303–7.
Mobasheri A, Saarakkala S, Finnilä M, Karsdal MA, Bay-Jensen A-C, van Spil WE. Recent advances in understanding the phenotypes of osteoarthritis. F1000Research. 2019;8:2091.
Oertel B, Lötsch J. NSAIDs, pharmacokinetics. In: Schmidt RF, Willis WD, editors. Encyclopedia of pain. Berlin: Springer, Berlin Heidelberg; 2007. p. 1479–87.
Gupta RC, Lall R, Srivastava A, Sinha A. Hyaluronic acid: Molecular mechanisms and therapeutic trajectory. Frontiers in veterinary science. 2019;6:192.
Derendorf H, Möllmann H, Grüner A, Haack D, Gyselby G. Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. Clin Pharmacol Ther. 1986;39(3):313–7.
Cooper C, Rannou F, Richette P, Bruyère O, Al-Daghri N, Altman RD, et al. Use of intraarticular hyaluronic acid in the management of knee osteoarthritis in clinical practice. Arthritis Care Res. 2017;69(9):1287–96.
Saengnipanthkul S, Waikakul S, Rojanasthien S, Totemchokchyakarn K, Srinkapaibulaya A, Cheh Chin T, et al. Differentiation of patented crystalline glucosamine sulfate from other glucosamine preparations will optimize osteoarthritis treatment. Int J Rheum Dis. 2019;22(3):376–85.
Maheu E, Rannou F, Reginster J-Y. Efficacy and safety of hyaluronic acid in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016;45(4 Suppl):S28–33.
Migliore A, Blicharski T, Plebanski R, Zegota Z, Gyula G, Rannou F, et al. Knee Osteoarthritis pain management with an innovative high and low molecular weight hyaluronic acid formulation (HA-HL): a randomized clinical trial. Rheumatol Ther. 2021;8(4):1617–36.
Nicholls E, Thomas E, Van der Windt D, Croft P, Peat G. Pain trajectory groups in persons with, or at high risk of, knee osteoarthritis: findings from the Knee Clinical assessment Study and the Osteoarthritis Initiative. Osteoarthr Cartil. 2014;22(12):2041–50.
de Wit M. The patient perspective. In: Hochberg G, Silman S, Weinblatt W, editors. Rheumatology. Elsevier; 2017. p. 409–12.
Schoemaker CG, van der Heijden GJ. Does GRADE gently close the door on sharing decisions with patients? J Clin Epidemiol. 2018;102:146–7.
Armstrong MJ, Mullins CD, Gronseth GS, Gagliardi AR. Impact of patient involvement on clinical practice guideline development: a parallel group study. Implement Sci. 2018;13(1):1–13.
